Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  AbbVie    ABBV

ABBVIE (ABBV)
Mes dernières consult.
Most popular
Report
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
 News SummaryMost relevantAll newsSector newsTweets
Most relevant news about ABBVIE
10/19 ABBVIE (NYSE : ABBV) Discloses Collaboration With Harpoon Therapeutics To Conduc..
10/18 ABBVIE : and Harpoon Therapeutics Announce Immuno-Oncology Research Collaboratio..
10/18 ABBVIE : to Present at the 2017 Credit Suisse Health Care Conference
10/13 ABBVIE : Demonstrates Leadership in HCV with New MAVYRET Data to be Presented at..
10/12 ABBVIE : and Turnstone Biologics Announce Global Collaboration on Viral Immunoth..
10/12 ABBVIE : ex-dividend day
10/11 ABBVIE : Demonstrates Leadership in HCV with New MAVYRET™ (glecaprevir/pib..
10/11 ABBVIE : to Host Third - Quarter 2017 Earnings Conference Call
10/10 ABBVIE : Collierville man awarded $140 million in lawsuit over testosterone drug..
10/10 ABBVIE : and Turnstone Biologics Announce Global Collaboration on Viral Immunoth..
10/09 ABBVIE : to Host Third-Quarter 2017 Earnings Conference Call
10/06 ABBVIE : NICE recommends access to venclyxto for adult leukaemia
10/04 ABBVIE : Confronting the Aftermath of a Month of Devastating Natural Disasters
10/03 Cannabis Market Extends across Numerous Industry Segments
10/02 AMGEN : And AbbVie Agree To Settlement Allowing Commercialization Of AMGEVITA
More most relevant news
All news about ABBVIE
10/19 ABBVIE : Researchers from AbbVie Report Findings in Medicinal Chemistry [Are We ..
10/19 ENANTA PHARMACEUTICALS : Announces Data to be Presented on AbbVie's MAVYRET&trad..
10/19 ABBVIE (NYSE : ABBV) Discloses Collaboration With Harpoon Therapeutics To Conduc..
10/18 ABBVIE : and Harpoon Therapeutics Announce Immuno-Oncology Research Collaboratio..
10/18 ABBVIE : to Present at the 2017 Credit Suisse Health Care Conference
10/13 ABBVIE : obtains licence for Turnstone Biologics oncolytic viral immunotherapies
10/13 ABBVIE : Demonstrates Leadership in HCV with New MAVYRET Data to be Presented at..
10/12 ABBVIE : and Turnstone Biologics Announce Global Collaboration on Viral Immunoth..
10/12 ABBVIE : ex-dividend day
10/11 ABBVIE : Demonstrates Leadership in HCV with New MAVYRET™ (glecaprevir/pib..
More news
Sector news : Specialty & Advanced Pharmaceuticals
10/21 JOHNSON & JOHNSON : California judge tosses $417 million talc cancer verdict aga..
10/20DJMERCK AND : to Lay Off About 1,800 U.S. Sales Reps in Cost-Cutting Move
10/20 MERCK AND : to cut 1,800 U.S. sales jobs, add 960 in chronic care
10/20DJABBOTT LABORATORIES : Hacking Is a Risk for Pacemakers. So Is the Fix
10/19DJCELGENE : Halts Crohn's Disease Drug Trials
10/19DJEuropean Corporate Roundup for Thursday
More sector news : Specialty & Advanced Pharmaceuticals
News from SeekingAlpha
10/19 FDA Approval Of Gilead CAR-T Therapy Will Move The Needle
10/18 Only 16 Of 61 Are 'Safer' Dividend Healthcare Dogs For October
10/18 AbbVie teams up with Harpoon Therapeutics in immuno-oncology; shares up 1% pr..
10/17 FFF PORTFOLIO : Nam Tai Takes Off And Adding Qualcomm
10/16 BIOTECH FORUM DAILY DIGEST : Aratana Therapeutics Back In The Spotlight
10/16 President Trump at it again with comments on "out of control" drug prices
Latest Tweets
12:20pMaking Marijuana Safer: Jessica Versteeg Explains Paragon Coin, The New Canna.. 
01:42aHow $ABBV calls soared tenfold
2
01:42aHow $ABBV calls soared tenfold
3
12:20aMaking Marijuana Safer: Jessica Versteeg Explains Paragon Coin, The New Canna.. 
10/21Lowe Brockenbrough & Co. Inc. Cuts Stake in AbbVie Inc. $ABBV  
More tweets
Qtime:184
Financials ($)
Sales 2017 27 965 M
EBIT 2017 11 938 M
Net income 2017 7 351 M
Debt 2017 25 677 M
Yield 2017 2,70%
P/E ratio 2017 20,17
P/E ratio 2018 16,40
EV / Sales 2017 6,40x
EV / Sales 2018 5,66x
Capitalization 153 B
Chart ABBVIE
Duration : Period :
AbbVie Technical Analysis Chart | ABBV | US00287Y1091 | 4-Traders
Technical analysis trends ABBVIE
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 20
Average target price 92,7 $
Spread / Average Target -3,6%
EPS Revisions
Managers
NameTitle
Richard A. Gonzalez Chairman & Chief Executive Officer
Azita Saleki-Gerhardt Senior Vice President-Operations
William J. Chase Chief Financial Officer & Executive Vice President
Michael E. Severino Chief Scientific Officer & Executive VP
Robert J. Alpern Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
ABBVIE53.37%153 193
MERCK KGAA-4.68%14 304
KYOWA HAKKO KIRIN CO LTD24.97%10 266
JAZZ PHARMACEUTICALS PLC28.83%8 652
ZHANGZHOU PIENTZEHUANG PHARMACEUTICL LTD33.70%5 811
CONVATEC GROUP-9.02%5 505